Medtronic says Evolut TAVR outperformed Edwards Sapien in trial

Medtronic (NYSE: MDT) today announced data from a head-to-head trial backing its Evolut TAVR system against the Edwards Sapien platform.

Related Keywords

Jeffrey Popma ,Howardc Herrmann ,Nina Goodheart ,University Of Pennsylvania ,American College Of Cardiology Annual Scientific Session ,Medtronic ,Perelman School Of Medicine ,American College ,Cardiology Annual Scientific ,New England Journal ,Structural Heart ,Cardiovascular Portfolio ,Perelman School ,Renal Denervation ,